Elevated luteinizing hormone in serum, breast cancer tissue, and normal breast tissue from breast cancer patients

Breast Cancer Research and Treatment

Volumn 76, Issue 2, 2002, Pages 125-130

  Silva, Elvio G ^a   Mistry, Dinu ^b   Li, Donghui ^a   Kuerer, Henry M ^a   Atkinson, Edward N ^a   Lopez, Abel N ^a   Shannon, Rhonda ^c   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Breast cancer; Luteinizing hormone

Indexed keywords

ESTROGEN RECEPTOR; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST; BREAST CANCER; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; SERUM;

ADULT; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; LUTEINIZING HORMONE; MENOPAUSE; MIDDLE AGED;

EID: 0036829441     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020528722842     Document Type: Article

References (18)

1. Russo J, Russo IH: Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomark Prev 3: 353-364, 1994
2. Russo J, Russo IH: Hormonally induced differentiation: A novel approach to breast cancer prevention. J Cell Biochem 22(suppl): 58-64, 1995
3. Abu-Bedair FA, El-Gamal BA, Ibrahim NA, El-Aaser AA: Hormonal profiles and estrogen receptors in Egyptian female cancer patients. Tumori 86: 24-29, 2000
4. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR: Disordered nocturnal prolactin regulation in women with breast cancer. Cancer Res 37: 650-654, 1977
5. Cramer DW, Petterson KSI, Barbieri RL, Huhtaniemi IT: Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone. Hum Reprod 15: 2103-2107, 2000
6. Gunasegaram R, Peh KL, Loganath A, Ang LC, Thiagaraj D, Kottegoda SR, Ratnam SS: Inappropriate luteinizing hormone concentration in human breast cancer. Aust N Z J Surg 55: 127-131, 1985
7. Thorner MO, Vance ML, Horvath E, Kovacs K: The anterior pituitary. In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology. 8th Edn, W.B. Saunders, Philadelphia, 1992, pp 221-310
8. Carr BR: Disorders of the ovary and female reproductive tract. In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology. 8th Edn, W.B. Saunders, Philadelphia, 1992, pp 733-798
9. Meduri G, Charnaux N, Loosfelt H, Jolivet A, Spyratos F, Brailly S, Milgrom E: Luteinizing/human chorionic gonadotropin in receptors in breast cancer. Cancer Res 57: 857-864, 1997
10. Asoci M, Segaloff DH: On the fates of receptor-bound ovine luteinizing hormone and human chorionic gonadotropin in cultured Leydig tumor cells. Demonstration of similar rates of internalization. Endocrinol 120: 1161-1172, 1987
11. Lojun S, Bao S, Lei ZM, Rao CV: Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: Implications supporting the premise that hCG protects women against breast cancer. Biol Reprod 57: 1202-1210, 1997
12. Rao CV: Does full-term pregnancy at a young age protect women against breast cancer through hCG? Obstet Gynecol 96: 783-786, 2000
13. Acevedo HF, Raikow RB, Powell JE, Stevens VC: Effects of immunization against human choriogonadotropin on the growth of transplanted Lewis lung carcinoma and spontaneous mammary adenocarcinoma in mice. Cancer Detect Prev 1 (suppl): 477-486, 1987
14. Höffken K, Kath R: The role of LH-RH analogues in the adjuvant and palliative treatment of breast cancer. Recent Results Cancer Res 153: 61-70, 2000
15. Jonat W: Luteinizing hormone-releasing hormone analogues - The rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer 4(suppl): 5-8, 1998
16. Klijn JG, Beex LV, Mauriac L. van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L: Combined treatment with Buserelin and Tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92: 903-911, 2000
17. Cockshott ID: Clinical pharmacokinetics of goserelin. Clin Pharmacokinetics 39: 24-48, 2000
18. Schally AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1247-1262, 1999